Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection (Q35082167)

6 August 2017

1 reference

title

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection (English)

1 reference

6 August 2017

0 references

1 reference

3

Hans-Peter Hartung

1 reference

6 August 2017

Oliver Neuhaus

1

1 reference

6 August 2017

Juan J Archelos

series ordinal

2

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Trends in Pharmacological Sciences

6 August 2017

published in

1 reference

6 August 2017

volume

24

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

131-138

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

6 August 2017

1 reference

7 January 2021

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

New concepts in the immunopathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Innate and adaptive immune responses can be beneficial for CNS repair

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Therapeutic developments in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Multiple sclerosis: a two-stage disease

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

1 reference

7 January 2021

A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

A functional and structural basis for TCR cross-reactivity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Oligoclonal expansion of memory CD8 T cells in cerebrospinal fluid from multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Axonal pathology in multiple sclerosis: relationship to neurologic disability

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Axon pathology in neurological disease: a neglected therapeutic target

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Molecular pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Nuclear factor-kappa B.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

The structure of human interferon-beta: implications for activity

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Therapeutic strategies in multiple sclerosis. I. Immunotherapy

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

1 reference

7 January 2021

Evaluation of mitoxantrone for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

The role of integrins in immune-mediated diseases of the nervous system

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Cell adhesion: old and new questions

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Alpha 4 integrin antagonists

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Functional Interactions of Neurotrophins and Neurotrophin Receptors

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Growth factor treatment of demyelinating disease: at last, a leap into the light.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Combinations of drugs

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Combination therapy for treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Drug treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

BMT beats autoimmune disease

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

How promising is hematopoetic stem cell transplantation in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Cell transplantation, myelin repair, and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Towards the reconstruction of central nervous system white matter using neural precursor cells

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

What roles do growth factors play in CNS remyelination?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

A new role for glia: generation of neurons!

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Glutamate excitotoxicity in a model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

Immunotherapy of multiple sclerosis: where are we? Where should we go?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(03)50028-2

7 January 2021

10.1016/S0165-6147(03)00028-2

Identifiers

DOI

1 reference

6 August 2017

1 reference